Board Meeting Details

The Board of Directors meeting was held on November 13, 2026, commencing at 11:45 AM and concluding at 01:05 PM. The meeting approved the un-audited standalone and consolidated financial results for the half year ended September 30, 2026.

Financial Results - Standalone (All amounts in ₹ Lakhs)

Income Statement Highlights:

  • Revenue from Operations: ₹21,162.92 (H1 FY27) vs ₹16,580.93 (H1 FY26)
  • Total Income: ₹21,242.70 (H1 FY27) vs ₹16,633.51 (H1 FY26)
  • Profit Before Tax: ₹1,562.98 (H1 FY27) vs ₹1,250.59 (H1 FY26)
  • Profit After Tax: ₹1,163.67 (H1 FY27) vs ₹819.52 (H1 FY26)
  • Earnings Per Share (Basic & Diluted): ₹4.97 (H1 FY27) vs ₹3.50 (H1 FY26)

Balance Sheet Highlights:

  • Share Capital: ₹2,340.50 (unchanged from March 31, 2026)
  • Reserves and Surplus: ₹11,085.95 (increased from ₹9,922.29)
  • Long Term Borrowings: ₹656.92 (increased from ₹356.80)
  • Short Term Borrowings: ₹11,168.98 (increased from ₹8,716.87)
  • Total Assets: ₹37,661.78 (increased from ₹31,096.47)

Cash Flow Highlights:

  • Net cash from Operating Activities: ₹931.95
  • Net cash used in Investing Activities: (₹672.01)
  • Net cash from Financing Activities: ₹2,133.15
  • Net increase in cash: ₹2,393.09
  • Cash and Bank Balances: ₹6,332.99 (increased from ₹3,939.90)

Financial Results - Consolidated (All amounts in ₹ Lakhs)

Income Statement Highlights:

  • Revenue from Operations: ₹21,162.92 (H1 FY27) vs ₹16,580.93 (H1 FY26)
  • Profit Before Tax: ₹1,554.18 (H1 FY27) vs ₹1,246.54 (H1 FY26)
  • Profit After Tax: ₹1,154.87 (H1 FY27) vs ₹815.46 (H1 FY26)
  • Earnings Per Share (Basic & Diluted): ₹4.93 (H1 FY27) vs ₹3.72 (H1 FY26)

Subsidiary Information:

  • Mahamaya Lifesciences (FZE) - Wholly Owned Subsidiary
  • Total assets: ₹38.25 lakhs as at September 30, 2026
  • Revenue: Nil for H1 FY27
  • Net loss after tax: ₹8.80 lakhs for H1 FY27
  • Total capital contribution planned: AED 150,000, of which AED 25,000 already remitted (AED 10,000 in 2018 & AED 15,000 in 2019)

IPO Proceeds Utilization

As certified by Statutory Auditor on November 3, 2026:

Utilization Summary:

  • Total IPO Proceeds Allocated: ₹61.96 crore
  • Amount Utilized during Period: ₹32.72 crore
  • Unutilized Amount: ₹29.24 crore

Breakdown of Utilization:

1. Purchase of Equipment for Fungicides, Insecticides and Bio-fermented formulations: ₹1.27 crore utilized (₹1.71 crore unutilized)

2. Purchase of Equipment for herbicides: ₹0.22 crore utilized (₹0.55 crore unutilized)

3. Funding of capital expenditure for new technical manufacturing plant: ₹3.13 crore utilized (₹26.28 crore unutilized)

4. Construction of Warehouse and purchase of machinery: ₹1.83 crore utilized (₹0.70 crore unutilized)

5. Funding of Working capital: ₹18.00 crore utilized (fully utilized)

6. General Corporate purpose: ₹8.26 crore utilized (fully utilized)

Unutilized Funds Deployment:

  • ₹1.72 crore balance in Monitoring Account
  • ₹27.52 crore deposited in Fixed Deposits with various banks:
  • DBS Bank: Multiple deposits totaling ₹10,02,00,000 (tenures 122-367 days)
  • Yes Bank: ₹7,50,00,000 (181 days)
  • Axis Bank: ₹5,00,00,000 (185 days)
  • HDFC Bank: Multiple deposits totaling ₹5,00,00,000 (30-274 days)

Business Segment and Seasonal Factors

The Company has only one reportable business segment: "Agro Chemicals". The demand for company's products depends on monsoon, pest infestation and crop patterns, which may cause variations in results from one period to another.

Company Listing History

The company was listed on the stock exchange on November 18, 2025. The public issue comprised 61,78,800 equity shares (56,38,800 fresh issue + 5,40,000 offer for sale by promoters) at issue price of ₹114 per share (face value ₹10 + premium ₹104).